Oncology Central

Screening for prostate cancer in the elderly


Prostate cancer screening is extremely controversial these days. Although nearly 30,000 men die annually of the disease, a large randomized (although many patients in the nonscreening arm were screened) PLCO trial conducted in the USA showed no survival advantage for screening (rate ratio: 1.15; 95% CI: 0.86–1.54) [1]. In addition, despite large screening efforts in the USA, the rate of death from prostate cancer has largely remained unchanged. Epidemiological studies looking at the death rate from prostate cancer across various countries have found that death from prostate cancer often appears to be similar between countries that screen for cancer and those that do not [101]. Furthermore, a recent Cochrane review performed a meta-analysis using the aforementioned prostate-specific antigen (PSA) screening studies, including the PLCO and ERSPC studies.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.